Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists

Clinical Therapeutics

Volumn 37, Issue 3, 2015, Pages 483-493

  Lindamood, Christopher A ^a   Taylor, James R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

albiglutide; dulaglutide; exenatide; GLP 1 receptor agonists; liraglutide; lixisenatide

Indexed keywords

ANTIDIABETIC AGENT; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LIRAGLUTIDE; PEPTIDE; RGLP-1 PROTEIN; VENOM;

ADULT; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; HUMAN; HYPOGLYCEMIA; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; LIRAGLUTIDE; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; VENOMS;

EID: 84939958366     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.01.003     Document Type: Review

References (32)

1. American Diabetes Association Approaches to glycemic treatment Diabetes Care 38 suppl 1 2015 S41 S48
2. S.L. Norris, N. Lee, and S. Thakurta Exenatide efficacy and safety: a systematic review Diabet Med 26 2009 837 846
3. B.K. Sethi, V. Viswanathan, and A. Kumar Liraglutide in clinical practice: insights from LEAD programme Supplement to JAPI 58 2010 18 22
4. R. DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
5. S. Kahn, M. Cooper, and S. Del Prato Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future Lancet 383 2014 1068 1083
6. E. Bojanowska Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress Med Sci Monit 11 2005 RA271 RA278
7. D. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
8. T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913
9. M.B. Toft-Nielsen, M.B. Damholt, and S. Madsbad Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients J Clin Endocrinol Metab 86 2001 3717 3723
10. K.J. Hare, F.K. Knop, and M. Asmar Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus J Clin Endocrinol Metab 94 2009 4679 4687
11. M.A. Nauck, U. Niedereichholz, and R. Ettler Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 273 1997 E981 E988
12. J.B. Buse, D.J. Drucker, and K.L. Taylor DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 2010 1255 1261
13. D.J. Drucker, J.B. Buse, and K.L. Taylor Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
14. C. Wysham, R.M. Bergenstal, and J. Malloy DURATION 2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once weekly exenatide Diabet Med 28 2011 705 714
15. R.M. Bergenstal, C. Wysham, and L. MacConell Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
16. M. Diamant, L. Van Gaal, and B. Guerci Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial Lancet Diabetes Endocrinol 2 2014 2464 2473
17. D. Russell-Jones, R.M. Cuddihy, and M. Hanefeld Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4) Diabetes Care 35 2012 252 258
18. T. Blevins, J. Pullman, and J. Malloy DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
19. J.B. Buse, M. Nauck, and T. Forst Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized open label study Lancet 381 2013 117 124
20. J.S. Reusch, M.W. Stewart, and C.M. Perkins Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin Diabetes Obes Metab 16 2014 1257 1264
21. R. Reinhardt, M.A. Nauck, and M. Stewart HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract] Diabetologia 56 2013 S360
22. S.L. Johnson, B. Ahren, and M. Stewart HARMONY-3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin Diabetologia 56 2013 S8 S9
23. P.N. Weissman, M.C. Carr, and J. Ye HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 57 2014 2475 2484
24. M. Stewart, P. Home, and F. Yang 52-Week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with T2D: HARMONY 5 study [abstract] Diabetologia 56 2013 S361
25. J. Rosenstock, V. Fonseca, and J.L. Gross Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice daily prandial insulin lispro Diabetes Care 37 2014 2317 2325
26. R.E. Pratley, M.A. Nauck, and A.H. Barnett Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 2014 289 297
27. L. Leiter, M.C. Carr, and M. Stewart HARMONY-8: once weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment: week 26 results Diabetologia 56 2013 S361 S362
28. C. Wysham, T. Blevins, and R. Arakaki Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 37 2014 2159 2167
29. G. Umpierrez, S. Povedano, and F.P. Manghi Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 37 2014 2168 2176
30. K.M. Dungan, S.T. Povedano, and T. Forst Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 384 2014 1349 1357
31. Gibney, Michael. "AstraZeneca Looks to Pen Injector Approval to Turn Bydureon Diabetes Sales around." FierceDrugDelivery. Fierce Drug Delivery, 2014. Accessed January 26, 2015
32. ® (exenatide extended-release) [package insert]. Wilminton, DE: AstraZeneca Pharmaceuticals; 2014